pozanicline Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Pozanicline is a drug developed by Abbott, that has nootropic and neuroprotective effects. Animal studies suggested it useful for the treatment of ADHD and subsequent human trials have shown ABT-089 to be effective for this application. It binds with high affinity subtype-selective to the α4β2 nicotinic acetylcholine receptors and has partial agonism to the α6β2 subtype, but not the α7 and α3β4 subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class.   Wikipedia

Chemistry

  • SMILES: Cc1ncccc1OC[C@@H]1CCCN1
  • InChIKey: YRVIKLBSVVNSHF-JTQLQIEISA-N
  • Mol. Mass: 192.26
  • ALogP: 1.52
  • ChEMBL Molecule:
    pozanicline  
More Chemistry

Pharmacology

Alternative names

2-methyl-3-(2-pyrrolidinylmethoxy)pyridine dihydrochloride, (r)-isomer | 2-methyl-3-(2-pyrrolidinylmethoxy)pyridine dihydrochloride, (s)-isomer | 2-methyl-3-(2-pyrrolidinylmethoxy)pyridine, (s)-isomer | a-87089.0 | abt 089 | abt-089 | pozanicline

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Alzheimer Disease (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 2)

Tobacco Use Disorder (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue